Camel's milk ameliorates TNBS-induced colitis in rats via downregulation of inflammatory cytokines and oxidative stress

Food and Chemical Toxicology

Volumn 69, Issue , 2014, Pages 294-302

  Arab, Hany H ^a,b   Salama, Samir A ^a,c   Eid, Ahmed H ^a,d   Omar, Hany A ^a,e   Arafa, El Shaimaa A ^a,e   Maghrabi, Ibrahim A ^a  

^a TAIF UNIVERSITY   (Saudi Arabia)

^b CAIRO UNIVERSITY   (Egypt)

^c Al Azhar University   (Egypt)

^d NATIONAL ORGANIZATION FOR DRUG CONTROL AND RESEARCH NODCAR   (Egypt)

^e Beni Suef University   (Egypt)

Author keywords

Camel's milk; Caspase 3; Colitis; Inflammation; Oxidative stress; TNBS

Indexed keywords

2,4,6 TRINITROBENZENE SULFONIC ACID; CASPASE 3; CYTOKINE; GLUTATHIONE; INTERLEUKIN 10; LIPID PEROXIDE; MYELOPEROXIDASE; NITRIC OXIDE; SULFONIC ACID DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ANTIOXIDANT; CASPASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; PEROXIDASE; TRINITROBENZENESULFONIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; CAMEL; COLITIS; COLON INJURY; COLON LENGTH; COLON WEIGHT; CONTROLLED STUDY; DIET THERAPY; DIGESTIVE TRACT PARAMETERS; DISEASE SEVERITY; DOWN REGULATION; ENZYME ACTIVITY; ENZYME INHIBITION; HISTOPATHOLOGY; LEUKOCYTE MIGRATION; MILK; NONHUMAN; ORGAN WEIGHT; OXIDATIVE STRESS; RAT; ANIMAL; CHEMICALLY INDUCED; DRUG EFFECTS; LEUKOCYTE; METABOLISM; PATHOLOGY; WISTAR RAT;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIOXIDANTS; CAMELS; CASPASE 3; CASPASE INHIBITORS; COLITIS; CYTOKINES; DOWN-REGULATION; INTERLEUKIN-10; LEUKOCYTES; MILK; OXIDATIVE STRESS; PEROXIDASE; RATS, WISTAR; TRINITROBENZENESULFONIC ACID; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84900822237     PISSN: 02786915     EISSN: 18736351     Source Type: Journal    
DOI: 10.1016/j.fct.2014.04.032     Document Type: Article

References (59)

1. Agrawal R.P., Dogra R., Mohta N., Tiwari R., Singhal S., Sultania S. Beneficial effect of camel milk in diabetic nephropathy. Acta Biomed. 2009, 80:131-134.
2. Agrawal R.P., Jain S., Shah S., Chopra A., Agarwal V. Effect of camel milk on glycemic control and insulin requirement in patients with type 1 diabetes: 2-years randomized controlled trial. Eur. J. Clin. Nutr. 2011, 65:1048-1052.
3. Agrawal R.P., Sharma P., Gafoorunissa S.J., Ibrahim S.A., Shah B., Shukla D.K., Kaur T. Effect of camel milk on glucose metabolism in adults with normal glucose tolerance and type 2 diabetes in Raica community: a crossover study. Acta Biomed. 2011, 82:181-186.
4. Akcan A., Kucuk C., Sozuer E., Esel D., Akyildiz H., Akgun H., Muhtaroglu S., Aritas Y. Melatonin reduces bacterial translocation and apoptosis in trinitrobenzene sulphonic acid-induced colitis of rats. World J. Gastroenterol. 2008, 14:918-924.
5. Al-Ayadhi L.Y., Elamin N.E. Camel milk as a potential therapy as an antioxidant in autism spectrum disorder (ASD). Evid. Based Complement. Alternat. Med.: eCAM 2013, 602834.
6. Alhaj O.A., Taufik E., Handa Y., Fukuda K., Saito T., Urashima T. Chemical characterization of oligosaccharides in commercially pasteurized dromedary camel (Camelus dromedaries) milk. Int. Dairy J. 2013, 28:70-75.
7. Autschbach F., Braunstein J., Helmke B., Zuna I., Schurmann G., Niemir Z.I., Wallich R., Otto H.F., Meuer S.C. In situ expression of interleukin-10 in noninflamed human gut and in inflammatory bowel disease. Am. J. Pathol. 1998, 153:121-130.
8. Barada K.A., Mourad F.H., Sawah S.I., Khoury C., Safieh-Garabedian B., Nassar C.F., Tawil A., Jurjus A., Saade N.E. Up-regulation of nerve growth factor and interleukin-10 in inflamed and non-inflamed intestinal segments in rats with experimental colitis. Cytokine 2007, 37:236-245.
9. Becker C., Watson A.J., Neurath M.F. Complex roles of caspases in the pathogenesis of inflammatory bowel disease. Gastroenterology 2013, 144:283-293.
10. Beutler E., Duron O., Kelly B.M. Improved method for the determination of blood glutathione. J. Lab. Clin. Med. 1963, 61:882-888.
11. Borrelli F., Fasolino I., Romano B., Capasso R., Maiello F., Coppola D., Orlando P., Battista G., Pagano E., Di Marzo V., Izzo A.A. Beneficial effect of the non-psychotropic plant cannabinoid cannabigerol on experimental inflammatory bowel disease. Biochem. Pharmacol. 2013, 85:1306-1316.
12. Buege J.A., Aust S.D. Microsomal lipid peroxidation. Methods Enzymol. 1978, 52:302-310.
13. Cabrera C., Gimenez R., Lopez M.C. Determination of tea components with antioxidant activity. J. Agric. Food Chem. 2003, 51:4427-4435.
14. Crespo I., San-Miguel B., Prause C., Marroni N., Cuevas M.J., Gonzalez-Gallego J., Tunon M.J. Glutamine treatment attenuates endoplasmic reticulum stress and apoptosis in TNBS-induced colitis. PLoS ONE 2012, 7:e50407.
15. Cross R.K., Wilson K.T. Nitric oxide in inflammatory bowel disease. Inflamm. Bowel Dis. 2003, 9:179-189.
16. Dallak M. Camel's milk protects against cadmium chloride-induced hypochromic microcytic anemia and oxidative stress in red blood cells of white albino rats. Am. J. Pharmacol. Toxicol. 2009, 4:134-141.
17. Darwish H.A., Abd Raboh N.R., Mahdy A. Camel's milk alleviates alcohol-induced liver injury in rats. Food Chem. Toxicol. 2012, 50:1377-1383.
18. Eiserich J.P., Hristova M., Cross C.E., Jones A.D., Freeman B.A., Halliwell B., van der Vliet A. Formation of nitric oxide-derived inflammatory oxidants by myeloperoxidase in neutrophils. Nature 1998, 391:393-397.
19. El Agamy E.I., Ruppanner R., Ismail A., Champagne C.P., Assaf R. Antibacterial and antiviral activity of camel milk protective proteins. J. Dairy Res. 1992, 59:169-175.
20. El Agamy E.L., Nawar M., Shamsia S.M., Awad S., Haenlein G.F. Are camel milk proteins convenient to the nutrition of cow milk allergic children. Small Ruminant Res. 2009, 82:1-6.
21. Fernandes-Alnemri T., Litwack G., Alnemri E.S. CPP32, a novel human apoptotic protein with homology to Caenorhabditis elegans cell death protein Ced-3 and mammalian interleukin-1 beta-converting enzyme. J. Biol. Chem. 1994, 269:30761-30764.
22. Fiocchi C. Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology 1998, 115:182-205.
23. Ghiselli A., Serafini M., Natella F., Scaccini C. Total antioxidant capacity as a tool to assess redox status: critical view and experimental data. Free Radic. Biol. Med. 2000, 29:1106-1114.
24. Giris M., Erbil Y., Dogru-Abbasoglu S., Yanik B.T., Alis H., Olgac V., Toker G.A. The effect of heme oxygenase-1 induction by glutamine on TNBS-induced colitis. The effect of glutamine on TNBS colitis. Int. J. Colorectal Dis. 2007, 22:591-599.
25. Haversen L., Ohlsson B.G., Hahn-Zoric M., Hanson L.A., Mattsby-Baltzer I. Lactoferrin down-regulates the LPS-induced cytokine production in monocytic cells via NF-kappa B. Cell. Immunol. 2002, 220:83-95.
26. Huang Z., Zuo L., Zhang Z., Liu J., Chen J., Dong L., Zhang J. 3,3'-Diindolylmethane decreases VCAM-1 expression and alleviates experimental colitis via a BRCA1-dependent antioxidant pathway. Free Radic. Biol. Med. 2011, 50:228-236.
27. Krawisz J.E., Sharon P., Stenson W.F. Quantitative assay for acute intestinal inflammation based on myeloperoxidase activity. Assessment of inflammation in rat and hamster models. Gastroenterology 1984, 87:1344-1350.
28. Kretzmann N.A., Fillmann H., Mauriz J.L., Marroni C.A., Marroni N., Gonzalez-Gallego J., Tunon M.J. Effects of glutamine on proinflammatory gene expression and activation of nuclear factor kappa B and signal transducers and activators of transcription in TNBS-induced colitis. Inflamm. Bowel Dis. 2008, 14:1504-1513.
29. Kruidenier L., Kuiper I., Lamers C.B., Verspaget H.W. Intestinal oxidative damage in inflammatory bowel disease: semi-quantification, localization, and association with mucosal antioxidants. J. Pathol. 2003, 201:28-36.
30. Kucharzik T., Stoll R., Lugering N., Domschke W. Circulating antiinflammatory cytokine IL-10 in patients with inflammatory bowel disease (IBD). Clin. Exp. Immunol. 1995, 100:452-456.
31. Legrand D., Elass E., Carpentier M., Mazurier J. Lactoferrin: a modulator of immune and inflammatory responses. Cell. Mol. Life Sci. 2005, 62:2549-2559.
32. Martin A.R., Villegas I., Sanchez-Hidalgo M., de la Lastra C.A. The effects of resveratrol, a phytoalexin derived from red wines, on chronic inflammation induced in an experimentally induced colitis model. Br. J. Pharmacol. 2006, 147:873-885.
33. Millar A.D., Rampton D.S., Chander C.L., Claxson A.W., Blades S., Coumbe A., Panetta J., Morris C.J., Blake D.R. Evaluating the antioxidant potential of new treatments for inflammatory bowel disease using a rat model of colitis. Gut 1996, 39:407-415.
34. Miranda K.M., Espey M.G., Wink D.A. A rapid, simple spectrophotometric method for simultaneous detection of nitrate and nitrite. Nitric Oxide 2001, 5:62-71.
35. Morris G.P., Beck P.L., Herridge M.S., Depew W.T., Szewczuk M.R., Wallace J.L. Hapten-induced model of chronic inflammation and ulceration in the rat colon. Gastroenterology 1989, 96:795-803.
36. Neurath M., Fuss I., Strober W. TNBS-colitis. Int. Rev. Immunol. 2000, 19:51-62.
37. Nicholson D.W. Caspase structure, proteolytic substrates, and function during apoptotic cell death. Cell Death Differ. 1999, 6:1028-1042.
38. Ohman L., Simren M. Pathogenesis of IBS: role of inflammation, immunity and neuroimmune interactions. Nat. Rev. Gastroenterol. Hepatol. 2010, 7:163-173.
39. Ozdemir G., Inanc F. Zinc may protect remote ocular injury caused by intestinal ischemia reperfusion in rats. Tohoku J. Exp. Med. 2005, 206:247-251.
40. Ozturk A., Baltaci A.K., Mogulkoc R., Oztekin E., Sivrikaya A., Kurtoglu E., Kul A. Effects of zinc deficiency and supplementation on malondialdehyde and glutathione levels in blood and tissues of rats performing swimming exercise. Biol. Trace Elem. Res. 2003, 94:157-166.
41. Qin H.Y., Xiao H.T., Wu J.C., Berman B.M., Sung J.J., Bian Z.X. Key factors in developing the trinitrobenzene sulfonic acid-induced post-inflammatory irritable bowel syndrome model in rats. World J. Gastroenterol. 2012, 18:2481-2492.
42. Rangan U., Bulkley G.B. Prospects for treatment of free radical-mediated tissue injury. Br. Med. Bull. 1993, 49:700-718.
43. Ruemmele F.M., Seidman E.G., Lentze M.J. Regulation of intestinal epithelial cell apoptosis and the pathogenesis of inflammatory bowel disorders. J. Pediatr. Gastroenterol. Nutr. 2002, 34:254-260.
44. Salami M., Moosavi-Movahedi A.A., Moosavi-Movahedi F., Ehsani M.R., Yousefi R., Farhadi M., Niasari-Naslaji A., Saboury A.A., Chobert J.M., Haertle T. Biological activity of camel milk casein following enzymatic digestion. J. Dairy Res. 2011, 78:471-478.
45. Salim S.Y., Soderholm J.D. Importance of disrupted intestinal barrier in inflammatory bowel diseases. Inflamm. Bowel Dis. 2011, 17:362-381.
46. Sanchez-Munoz F., Dominguez-Lopez A., Yamamoto-Furusho J.K. Role of cytokines in inflammatory bowel disease. World J. Gastroenterol. 2008, 14:4280-4288.
47. Schreiber S., Heinig T., Thiele H.G., Raedler A. Immunoregulatory role of interleukin 10 in patients with inflammatory bowel disease. Gastroenterology 1995, 108:1434-1444.
48. Southey A., Tanaka S., Murakami T., Miyoshi H., Ishizuka T., Sugiura M., Kawashima K., Sugita T. Pathophysiological role of nitric oxide in rat experimental colitis. Int. J. Immunopharmacol. 1997, 19:669-676.
49. Tanida S., Mizoshita T., Mizushima T., Sasaki M., Shimura T., Kamiya T., Kataoka H., Joh T. Involvement of oxidative stress and mucosal addressin cell adhesion molecule-1 (MAdCAM-1) in inflammatory bowel disease. J. Clin. Biochem. Nutr. 2011, 48:112-116.
50. Tomoyose M., Mitsuyama K., Ishida H., Toyonaga A., Tanikawa K. Role of interleukin-10 in a murine model of dextran sulfate sodium-induced colitis. Scand. J. Gastroenterol. 1998, 33:435-440.
51. Valko M., Leibfritz D., Moncol J., Cronin M.T., Mazur M., Telser J. Free radicals and antioxidants in normal physiological functions and human disease. Int. J. Biochem. Cell Biol. 2007, 39:44-84.
52. Witaicenis A., Luchini A.C., Hiruma-Lima C.A., Felisbino S.L., Garrido-Mesa N., Utrilla P., Galvez J., Di Stasi L.C. Suppression of TNBS-induced colitis in rats by 4-methylesculetin, a natural coumarin: comparison with prednisolone and sulphasalazine. Chem. Biol. Interact. 2012, 195:76-85.
53. Yamamoto-Furusho J.K. Innovative therapeutics for inflammatory bowel disease. World J. Gastroenterol. 2007, 13:1893-1896.
54. Yao J., Wang J.Y., Liu L., Li Y.X., Xun A.Y., Zeng W.S., Jia C.H., Wei X.X., Feng J.L., Zhao L., Wang L.S. Anti-oxidant effects of resveratrol on mice with DSS-induced ulcerative colitis. Arch. Med. Res. 2010, 41:288-294.
55. Yateem A., Balba M.T., Al Surrayai T., Al Mutairi B. Isolation of lactic acid bacteria with probiotic potential from camel milk. Int. J. Dairy Sci. 2008, 3:194-199.
56. Yousef M.I. Aluminium-induced changes in hemato-biochemical parameters, lipid peroxidation and enzyme activities of male rabbits: protective role of ascorbic acid. Toxicology 2004, 199:47-57.
57. Zhang H., Yao J., Zhao D., Liu H., Li J., Guo M. Changes in chemical composition of Alxa bactrian camel milk during lactation. J. Dairy Sci. 2005, 88:3402-3410.
58. Zhou Y.H., Yu J.P., Liu Y.F., Teng X.J., Ming M., Lv P., An P., Liu S.Q., Yu H.G. Effects of Ginkgo biloba extract on inflammatory mediators (SOD, MDA, TNF-alpha, NF-kappaBp65, IL-6) in TNBS-induced colitis in rats. Mediators Inflamm. 2006, 2006:92642.
59. Zhu H., Li Y.R. Oxidative stress and redox signaling mechanisms of inflammatory bowel disease: updated experimental and clinical evidence. Exp. Biol. Med. (Maywood) 2012, 237:474-480.